{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-356877","form_type":"8-K","ticker":"KRRO","cik":"0001703647","company_name":"Korro Bio, Inc.","filed_at":"2026-08-19T20:05:15+00:00","discovered_at":"2026-08-19T20:06:00.691968+00:00","generated_at":"2026-08-19T20:06:11.255097+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Korro Bio submits to Australian ethics committee to begin Phase 1/2 trial for KRRO-121 in UCDs","bullets":["Submission to Alfred Health Human Ethics Committee to start first-in-human Phase 1/2 trial of KRRO-121.","KRRO-121 is a GalNAc-conjugated RNA editing oligonucleotide targeting hyperammonemia in Urea Cycle Disorders.","Trial will evaluate safety, tolerability of escalating doses, and pharmacokinetics in healthy volunteers and UCD patients.","Listed on ClinicalTrials.gov as NCT07773246.","No clinical data released yet; first-in-human milestone for the program."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-356877","json":"https://secwatch.observer/filing/0001193125-26-356877.json","markdown":"https://secwatch.observer/filing/0001193125-26-356877.md","text":"https://secwatch.observer/filing/0001193125-26-356877.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703647/000119312526356877/0001193125-26-356877-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703647/000119312526356877/krro-20260819.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-19T20:06:11.255097+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}